🇺🇸 Pyrimethamine/sulfadoxine in United States

177 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 177

Most-reported reactions

1. Small For Dates Baby — 56 reports (31.64%)
2. Death — 27 reports (15.25%)
3. Stillbirth — 27 reports (15.25%)
4. Death Neonatal — 18 reports (10.17%)
5. Maternal Drugs Affecting Foetus — 10 reports (5.65%)
6. Squamous Cell Carcinoma — 9 reports (5.08%)
7. Post Transplant Lymphoproliferative Disorder — 8 reports (4.52%)
8. Premature Baby — 8 reports (4.52%)
9. Abortion — 7 reports (3.95%)
10. Aspergillus Infection — 7 reports (3.95%)

Source database →

Frequently asked questions

Is Pyrimethamine/sulfadoxine approved in United States?

Pyrimethamine/sulfadoxine does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Pyrimethamine/sulfadoxine in United States?

London School of Hygiene and Tropical Medicine is the originator. The local marketing authorisation holder may differ — check the official source linked above.